HIV takes cellular opportunities to aid infection

May 19, 2004

Scientists will have a new view of how the AIDS virus (HIV) enters a target cell and begins its process of infection, thanks to a technique created by researchers at the Salk Institute.

The technique allows scientists to observe for the first time the steps taken by viruses like HIV after they enter a cell. The study was done with a chicken virus that was modified to contain the genes of HIV. Both the chicken virus and HIV are retroviruses, which means their genomes are made from RNA rather than DNA. When the viruses enter a host cell, their RNA genomes are converted to DNA, which integrates into the DNA of the host cell. This step is essential for the formation of new virus particles.

John Young, a Salk professor of infectious disease, and colleague Shakti Narayan reported their findings in the May 18 edition of the Proceedings of the National Academy of Sciences.

The research provides new insights into the chemical events that allow viruses like HIV to replicate within cells. Scientists have long known how HIV breaks into the host cell by merging with its surface layer. They've also known how the viral genome is copied and can hitch onto the cell's genetic material and begin expressing proteins that aid infection. But they didn't know the steps in between.

"This technique shows us what happens after the virus first steps in the door, and removes its coating," said Young. "We now know that molecules exist in cells that help the virus convert its RNA genome to DNA but we don't yet know what those molecules are. Once we identify them, which this system allows, we may be able to manipulate them to halt viral DNA synthesis, and produce a new therapy for AIDS." This new technique uses a test-tube system to study the chemical players in virus infectivity, thereby allowing scientists to analyze infectivity in a setting not complicated by other cellular structures.

AIDS is a major epidemic in many developing countries in Africa and Asia, and has been responsible for more than 500,000 deaths in the United States. About 47 million people worldwide are afflicted with AIDS.

AIDS is currently incurable. However, cocktails that contain chemical agents that block various steps of viral replication have allowed millions of people to survive with the disease. "This work could provide us with another class of molecules to add to the cocktail," said Young. "Once we identify cellular factors that regulate HIV replication, we may be able devise new treatments for other viral infections, as well."
-end-
The Salk Institute for Biological Studies, located in La Jolla, Calif., is an independent nonprofit organization dedicated to fundamental discoveries in the life sciences, the improvement of human health and conditions, and the training of future generations of researchers. Jonas Salk, M.D., founded the institute in 1960 with a gift of land from the City of San Diego and the financial support of the March of Dimes Birth Defects Foundation.

Salk Institute

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.